NCT05627245 2026-04-22
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
17 trialsNCT05983965 2026-04-17
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Terminated
NCT04241835 2026-04-16
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Ipsen
Phase 1 Terminated
NCT05353439 2026-04-13
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06824701 2026-04-06
TARZAN
University of Utah
Phase 1 Suspended
NCT05618366 2026-04-02
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Phase 1 Terminated
NCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
NCT05934838 2025-08-15
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
Phase 1 Recruiting
NCT04846478 2025-04-17
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT02601937 2024-10-03
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Ipsen
Phase 1 Completed
NCT03010982 2024-03-22
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Ipsen
Phase 1 Completed
NCT04624113 2024-02-21
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
Phase 1 Terminated
NCT03028103 2023-06-26
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Ipsen
Phase 1 Completed
NCT03009344 2022-11-10
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Inc.
Phase 1 Completed
NCT03217253 2020-02-07
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT02220842 2020-01-27
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed